Inhibrx Biosciences, Inc. INBX Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s other commercial liabilities?
- Inhibrx Biosciences, Inc. (INBX) reported other commercial liabilities of $15.34M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s other commercial liabilities changed year-over-year?
- Inhibrx Biosciences, Inc.'s other commercial liabilities decreased by 53.2% year-over-year, from $32.77M to $15.34M.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s other commercial liabilities?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s other commercial liabilities has grown at a -23.2% compound annual growth rate (CAGR), from $43.3M to $25.53M.